Recent findings on Ingrezza reveal that the medication significantly enhances the quality of life and daily functioning for individuals suffering from Tardive Dyskinesia. This groundbreaking data, highlighted by Psychiatric Times, underscores how Ingrezza can effectively alleviate the debilitating symptoms associated with this movement disorder. Patients reported noteworthy improvements in their daily activities, indicating that Ingrezza not only manages physical symptoms but also contributes to an overall improved well-being. As Tardive Dyskinesia often leads to social and functional difficulties, the positive impact of Ingrezza offers new hope for patients and healthcare providers seeking effective treatment options. With its ability to address both quality of life and functional capacity, Ingrezza stands out as a promising option in managing this challenging condition.
Psychiatric TimesNew data shows Back-to-School Shopping Costs Surge Compared to Previous Years
August 14, 2026
New data reveals that back-to-school shopping is more expensive this year than in previous years, adding a strain on parents’ budgets nationwide. The increase in